Tags : REGN-EB3

BARDA Signs a Multi-Year Agreement with Regeneron for its REGN-EB3

Shots: Regeneron will be responsible to deliver treatment doses for six years post-approval of product from the FDA, will receive compensation of ~$10M & average of $67M/year in 2021 and each for the next five years (2022-2026) respectively In 2019, the PALM trial evaluated REGN-EB3 vs ZMapp conducted in the Democratic Republic of the Congo, […]Read More

Regeneron Reports the US FDA’s Acceptance of Priority Review for

Shots: The BLA is supported by PALM clinical study conducted in the Democratic Republic of Congo. In Aug’2019, the trial was stopped early when preliminary results demonstrated that REGN-EB showed superiority over ZMapp REGN-EB3 demonstrated superior efficacy as compared to ZMapp across multiple measures, including reduced mortality and fewer days until the Ebola virus was […]Read More